Virginia Tech® home

Daniel Slade

Collegiate Assistant Professor
Caitlin Cridland
BIOCHEMISTRY MC0308
ENGEL HALL

Education

Postdoctoral Associate, Scripps Research Institute, 2011-2014

NIH Postdoctoral Fellow, Harvard Medical School, 208-2011

Ph.D., Biochemistry, University of South Carolina

B.S., Chemistry, Wofford College

Experience

2024 – Associate Professor of Practice, Virginia Tech, Department of Biochemistry

2024 – Associate, Outcome Capital, Boston MA

2021-2024 – Associate Professor, Virginia Tech, Department of Biochemistry

2014-2021 – Assistant Professor, Virginia Tech, Department of Biochemistry

Awards

Most Outstanding Teacher Award - Department of Biochemistry - Virginia Tech 2021

Most Outstanding Teacher Award - Department of Biochemistry - Virginia Tech 2017

Most Outstanding Research Award - Department of Biochemistry - Virginia Tech 2020

Session Curator and Moderator - ASM Microbe - ‘Bacteria in Tumor Microenvironments’ - 2020

Steering Committee - Virginia Tech Cancer Research Alliance - 2020-204

Ruth L Kirschstein NIH Postdoctoral Fellow - Harvard Medical School - 2009-2011

Courses Taught

BCHM 4124: Laboratory Problems in Biochemistry

BCHM 4115: General Biochemistry

BCHM 2024: Concepts of Biochemistry

BCHM 5225: Protein Structure and Function

BCHM 5784: Advanced Applications in Molecular Life Sciences

Dr. Slade’s PubMed Site: 44 publications (Link: https://www.ncbi.nlm.nih.gov/myncbi/daniel.slade.1/bibliography/public/)

Dr. Slade’s Google Scholar Site: (Link: https://scholar.google.com/citations?user=6GBJRY4AAAAJ&hl=en&authuser=1)

Select Publications

Udayasuryan B, Zhou Z, Ahmad RN, Sobol P, Deng C, Nguyen TTD, Kodikalla S, Morrison R, Goswami I, Slade DJ, Verbridge SS, Lu C. Fusobacterium nucleatum infection modulates the transcriptome and epigenome of HCT116 colorectal cancer cells in an oxygen-dependent manner. Commun Biol. 2024 May 8;7(1):551. PMID: 38720110.

Sanders BE, Umaña A, Nguyen TTD, Williams KJ, Yoo CC, Casasanta MA, Wozniak B, Slade DJ. Type IV pili facilitated natural competence in Fusobacterium nucleatum. Anaerobe. 2023 Aug;82:102760. PMID: 37451427.

Udayasuryan B, Ahmad RN, Nguyen TTD, Umaña A, Monét Roberts L, Sobol P, Jones SD, Munson JM, Slade DJ, Verbridge SS. Fusobacterium nucleatum induces proliferation and migration in pancreatic cancer cells through host autocrine and paracrine signaling. Sci Signal. 2022 Oct 18;15(756):eabn4948. PMID: 36256708.

Ternes D, Tsenkova M, Pozdeev VI, Meyers M, Koncina E, Atatri S, Schmitz M, Karta J, Schmoetten M, Heinken A, Rodriguez F, Delbrouck C, Gaigneaux A, Ginolhac A, Nguyen TTD, Grandmougin L, Frachet-Bour A, Martin-Gallausiaux C, Pacheco M, Neuberger-Castillo L, Miranda P, Zuegel N, Ferrand JY, Gantenbein M, Sauter T, Slade DJ, Thiele I, Meiser J, Haan S, Wilmes P, Letellier E. The gut microbial metabolite formate exacerbates colorectal cancer progression. Nat Metab. 2022 Apr;4(4):458-475. doi: 10.1038/s42255-022-00558-0. Epub 2022 Apr 18. Erratum in: Nat Metab. 2023 Sep;5(9):1638. PMID: 35437333.

Slade DJ. New Roles for Fusobacterium nucleatum in Cancer: Target the Bacteria, Host, or Both? Trends Cancer. 2021 Mar;7(3):185-187. PMID: 33309240.

Casasanta MA, Yoo CC, Udayasuryan B, Sanders BE, Umaña A, Zhang Y, Peng H, Duncan AJ, Wang Y, Li L, Verbridge SS, Slade DJ. Fusobacterium nucleatum host-cell binding and invasion induces IL-8 and CXCL1 secretion that drives colorectal cancer cell migration. Sci Signal. 2020 Jul 21;13(641):eaba9157. PMID: 32694172.